Markets JNJ

Johnson & Johnson Guides FY26 Sales Above Estimates - Update

January 21, 2026 — 06:43 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, drug major Johnson & Johnson (JNJ) initiated its adjusted earnings and sales guidance for the full-year 2026.

For fiscal 2026, the company now projects adjusted earnings in a range of $11.43 to $11.63 per share and adjusted operational earnings in a range of $11.28 to $11.48 per share on sales between $100 billion and $101 billion as well as operational sales between $99.5 billion and $100.5 billion, with adjusted operational sales growth of 5.4 to 6.4 percent.

On average, analysts polled expect the company to report earnings of $11.49 per share on sales of $98.77 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
JNJ

Latest Articles
Data is currently not available